Description

FRIIS Liquid Medium is specifically formulated for the qualitative detection of avian-derived mycoplasmas in pharmaceutical testing matrices, including bulk vaccine intermediates, master and working cell banks, and viral culture systems.

The basal composition of the medium is supplemented with nicotinamide adenine dinucleotide (NAD⁺) to meet the essential growth requirements of fastidious species such as Mycoplasma synoviae. The presence of mycoplasmas in test samples is indicated by a distinct colorimetric shift resulting from metabolic activity acting on the incorporated phenol red indicator.

To suppress background flora, selective antibiotics are incorporated into the formulation. Furthermore, the inclusion of exogenous lipid components from yolk significantly enhances the growth yield and colony-forming potential of lipid-requiring strains—most notably Mycoplasma pneumoniae ATCC 23714—by providing bioavailable cholesterol and fatty acids required for membrane biosynthesis and metabolic function.

Specifications

Agency	EP 2.6.7 / USP / JP
Quality Level	ISO 9001
Sterility	Sterile
-	Aseptically Filled
Form	Liquid
Feature	Ready-to-use; ICR Settle plates
packaging	1 bottle
Bottle Filling Volume	100 mL
pH	7.4 (in H2O)
Application(s)	Industrial qc
Storage Temp	2-8℃ for 6 months -20℃ -80℃ for 1 year
Suitability	Mycoplasma

Application

FRIIS Liquid Medium is designed for the detection of avian mycoplasmas in pharmaceutical test samples, particularly in bulk vaccines, cell banks, and viral cultures.

Features

Ready-to-use convenience — no additional preparation steps are required.
Broad pharmaceutical applications — suitable for biopharmaceuticals, vaccines, cell cultures, and virus cultures.
Storage stability — can be stored at 2–8 °C for up to 6 months or at −20 °C for 1 year.
Rapid detection — a colorimetric chart provides a quick and convenient visual indication of early-stage mycoplasma proliferation.
Optimized growth performance — the buffered system supports higher colony counts while reducing the risk of mycoplasma cell death.
Enhanced visualization — a chromogenic reagent selectively stains mycoplasma, improving clarity and specificity under microscopy.
Improved NAD⁺ stability — to prevent growth inhibition caused by NAD⁺ degradation during later stages, alternative NAD⁺ analogs are co-supplemented in the culture system.

Documents

M-FRIIS-Y SDS

Friis broth (M-FRIIS-Y)